CVS rises as investors revisit stronger guidance and fading Omnicare overhang

CVS Health (CVS) is up 3.7% today. Here is some analysis on what might have caused this price movement. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx?utm_source=openai))

Analysis: The move appears tied to a mix of improving sentiment around CVS Health’s stronger 2026 operating outlook and the reduced distraction from Omnicare’s court-approved wind-down. A clear single-day catalyst is not obvious, so part of the gain could also reflect investors buying a recent pullback in a stock that had drifted lower despite better earnings and guidance. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx?utm_source=openai))

Details:

CVS Health raised its full-year 2026 GAAP EPS, adjusted EPS, and cash flow from operations guidance after second-quarter results improved across major business segments. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx))

Second-quarter adjusted operating income rose across Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness, with the insurance unit helped by better government-business performance and a lower medical benefit ratio. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx))

Recent market commentary highlighted that the shares had been under pressure even after stronger quarterly execution, which can set up rebound buying when sentiment stabilizes. ([finance.yahoo.com](https://finance.yahoo.com/quote/CVS/?p=CVS&utm_source=openai))

Omnicare’s bankruptcy plan won court approval after the business had already been sold, which may be seen as one more step in cleaning up a long-running legal and operational overhang for CVS. ([news.bloomberglaw.com](https://news.bloomberglaw.com/mergers-and-acquisitions/cvs-unit-omnicare-bankruptcy-plan-approved-after-sale-doj-deal?utm_source=openai))

Sources:

CVS Health, Bloomberg Law, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CVS Insider Trading Activity

$CVS insiders have traded $CVS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $CVS stock by insiders over the last 6 months:

LARRY ROBBINS has made 0 purchases and 7 sales selling 3,372,000 shares for an estimated $317,471,136.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$CVS Hedge Fund Activity

We have seen 1,085 institutional investors add shares of $CVS stock to their portfolio, and 955 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 22,112,970 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,287,586,746
BANK OF AMERICA CORP /DE/ added 13,836,701 shares (+148.0%) to their portfolio in Q2 2026, for an estimated $1,431,406,718
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 13,259,314 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,371,676,033
WELLINGTON MANAGEMENT GROUP LLP added 11,233,381 shares (+49.8%) to their portfolio in Q2 2026, for an estimated $1,162,093,264
GQG PARTNERS LLC added 7,923,888 shares (+25136.8%) to their portfolio in Q2 2026, for an estimated $819,726,213
INVESCO LTD. removed 4,543,515 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $470,026,626
WELLS FARGO & COMPANY/MN removed 4,428,857 shares (-54.6%) from their portfolio in Q2 2026, for an estimated $458,165,256

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CVS Government Contracts

We have seen $5,680,406 of award payments to $CVS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EFFECTIVENESS AND SAFETY (BES...: $5,476,406

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$CVS Congressional Stock Trading

Members of Congress have traded $CVS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CVS stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$CVS Price Targets

Multiple analysts have issued price targets for $CVS recently. We have seen 15 analysts offer price targets for $CVS in the last 6 months, with a median target of $108.0.

Here are some recent targets:

Ben Hendrix from RBC Capital set a target price of $113.0 on 07/09/2026
Sarah James from Cantor Fitzgerald set a target price of $110.0 on 07/07/2026
Allen Lutz from B of A Securities set a target price of $110.0 on 06/23/2026
Ann Hynes from Mizuho set a target price of $115.0 on 06/08/2026
Erin Wright from Morgan Stanley set a target price of $111.0 on 06/04/2026
David Macdonald from Truist Securities set a target price of $108.0 on 06/01/2026
Andrew Mok from Barclays set a target price of $106.0 on 05/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.